Of note, A-1331852 has a stronger affinity for Bcl-xL than Navitoclax and is comparatively more potent to impair the growth of Bcl-xL-dependent tumor cells (Leverson et al, 2015). This evidence concerns the gene BCL2L1 and neoplasm.